Amphotericin B releasing topical nanoemulsion for the treatment of candidiasis and aspergillosis

The present study was designed to develop a nanoemulsion formulation of Amphotericin B (AmB) for the treatment of skin candidiasis and aspergillosis. Several ingredients were selected on the basis of AmB solubility and compatibility with skin. The formulation that exhibited the best properties was selected from the pseudo-ternary phase diagram. After physicochemical characterization its stability was assessed. Drug release and skin permeation studies were also accomplished. The antifungal efficacy and skin tolerability of developed AmB nanoemulsion was demonstrated. Finally, our results showed that the developed AmB formulation could provide an effective local antifungal effect without theoretical systemic absorption, based on its skin retention capacity, which might avoid related side effect. These results suggested that the nanoemulsion may be an optimal therapeutic alternative for the treatment of skin fungal infections with AmB. To develop a therapeutic tool against skin candidiasis and aspergillosis with amphotericin B, a nanoemulsion delivery system was developed performing the pseudo-ternary phase diagram of components with reported skin compatibility. The nanosystem vehicle was then characterized in terms of size, stability, rheology, and release properties. Furthermore, human skin permeation (ex vivo) and tolerance (in vivo) was evaluated, as well as, its antifungal efficacy. Results demonstrated that the amphotericin B nanoemulsion could provide a local skin effect avoiding theoretical systemic absorption assuring its safety. [Display omitted]